ES2450423T3 - Composición farmacéutica que comprende propofol - Google Patents
Composición farmacéutica que comprende propofol Download PDFInfo
- Publication number
- ES2450423T3 ES2450423T3 ES10778677.4T ES10778677T ES2450423T3 ES 2450423 T3 ES2450423 T3 ES 2450423T3 ES 10778677 T ES10778677 T ES 10778677T ES 2450423 T3 ES2450423 T3 ES 2450423T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- propofol
- dosage form
- oral
- fluorinated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C19/00—Acyclic saturated compounds containing halogen atoms
- C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09014548A EP2332525A1 (en) | 2009-11-23 | 2009-11-23 | Pharmaceutical composition comprising propofol |
| EP09014548 | 2009-11-23 | ||
| PCT/EP2010/067938 WO2011061332A1 (en) | 2009-11-23 | 2010-11-22 | Pharmaceutical composition comprising propofol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2450423T3 true ES2450423T3 (es) | 2014-03-24 |
Family
ID=41694756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10778677.4T Active ES2450423T3 (es) | 2009-11-23 | 2010-11-22 | Composición farmacéutica que comprende propofol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8796340B2 (enExample) |
| EP (2) | EP2332525A1 (enExample) |
| JP (1) | JP5707009B2 (enExample) |
| KR (1) | KR20120104262A (enExample) |
| CN (1) | CN102753159B (enExample) |
| AU (1) | AU2010320823B2 (enExample) |
| BR (1) | BR112012012108A2 (enExample) |
| CA (1) | CA2776855C (enExample) |
| ES (1) | ES2450423T3 (enExample) |
| IN (1) | IN2012DN03130A (enExample) |
| MX (1) | MX2012005881A (enExample) |
| WO (1) | WO2011061332A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP3192501B1 (en) | 2011-05-25 | 2020-05-13 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| GB201116271D0 (en) | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
| ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
| MY166228A (en) | 2012-09-12 | 2018-06-22 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| ES2682064T3 (es) * | 2012-09-12 | 2018-09-18 | Novaliq Gmbh | Composiciones para el lavado de ojos |
| EP4342537A3 (en) | 2012-09-12 | 2024-07-03 | Novaliq GmbH | Semifluorinated alkane compositions |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| EP3206683A4 (en) | 2014-10-16 | 2018-06-13 | The Board of Trustees of the Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
| DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
| CN113662928A (zh) | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
| BR112020006072A2 (pt) | 2017-09-27 | 2020-10-06 | Novaliq Gmbh | composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares |
| CN119909046A (zh) | 2017-10-04 | 2025-05-02 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| BR112022004677A2 (pt) | 2019-09-06 | 2022-05-17 | Novaliq Gmbh | Composição oftálmica para o tratamento de uveíte |
| EP3912622A1 (en) | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Oral film for safe administration of api |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496537A (en) * | 1995-03-23 | 1996-03-05 | Henry; Richard A. | Propofol hydrofluorocarbon propellant formulations |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| EP1124416A1 (en) * | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| GB0124071D0 (en) * | 2001-10-08 | 2001-11-28 | Kbig Ltd | Improvement in the administration of high boiling point aneasthetics |
| WO2005067517A2 (en) * | 2004-01-02 | 2005-07-28 | Wisconsin Alumni Research Foundation | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| JP5569899B2 (ja) * | 2006-11-28 | 2014-08-13 | ウィスコンシン・アラムナイ・リサーチ・ファウンデーション | 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション |
| EP2110126B9 (de) | 2008-04-18 | 2012-09-19 | Novaliq GmbH | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
-
2009
- 2009-11-23 EP EP09014548A patent/EP2332525A1/en not_active Withdrawn
-
2010
- 2010-11-22 JP JP2012539355A patent/JP5707009B2/ja active Active
- 2010-11-22 CA CA2776855A patent/CA2776855C/en active Active
- 2010-11-22 US US13/511,184 patent/US8796340B2/en active Active
- 2010-11-22 BR BR112012012108A patent/BR112012012108A2/pt not_active Application Discontinuation
- 2010-11-22 ES ES10778677.4T patent/ES2450423T3/es active Active
- 2010-11-22 KR KR1020127016348A patent/KR20120104262A/ko not_active Withdrawn
- 2010-11-22 CN CN201080052400.7A patent/CN102753159B/zh active Active
- 2010-11-22 MX MX2012005881A patent/MX2012005881A/es not_active Application Discontinuation
- 2010-11-22 IN IN3130DEN2012 patent/IN2012DN03130A/en unknown
- 2010-11-22 AU AU2010320823A patent/AU2010320823B2/en active Active
- 2010-11-22 WO PCT/EP2010/067938 patent/WO2011061332A1/en not_active Ceased
- 2010-11-22 EP EP10778677.4A patent/EP2503999B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102753159B (zh) | 2014-03-12 |
| AU2010320823B2 (en) | 2014-06-26 |
| CA2776855C (en) | 2017-10-24 |
| US8796340B2 (en) | 2014-08-05 |
| WO2011061332A1 (en) | 2011-05-26 |
| JP5707009B2 (ja) | 2015-04-22 |
| US20120238639A1 (en) | 2012-09-20 |
| EP2332525A1 (en) | 2011-06-15 |
| IN2012DN03130A (enExample) | 2015-09-18 |
| KR20120104262A (ko) | 2012-09-20 |
| MX2012005881A (es) | 2012-06-19 |
| EP2503999A1 (en) | 2012-10-03 |
| CA2776855A1 (en) | 2011-05-26 |
| AU2010320823A1 (en) | 2012-07-12 |
| EP2503999B1 (en) | 2013-12-25 |
| JP2013511496A (ja) | 2013-04-04 |
| BR112012012108A2 (pt) | 2016-04-05 |
| CN102753159A (zh) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2450423T3 (es) | Composición farmacéutica que comprende propofol | |
| JP2021193091A (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| US20140113971A1 (en) | Topical NSAID Compositions Having Sensate Component | |
| US5496537A (en) | Propofol hydrofluorocarbon propellant formulations | |
| US20150231130A1 (en) | Pharmaceutical composition comprising diamorphine for intranasal administration | |
| JP2023547040A (ja) | ピロロピリジン－アニリン化合物による、認知機能不全の処置方法 | |
| US20110237674A1 (en) | Topical nsaid compositions having sensate component | |
| JP5210486B2 (ja) | ハロゲン化揮発性麻酔剤の静脈投与による、心臓保護および神経保護のための方法 | |
| ES2935684T3 (es) | Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades | |
| KR20100112632A (ko) | 수용성인 프로포폴 전구약물의 약제학적 수성 제제 | |
| JP2006504740A5 (enExample) | ||
| PT2197492E (pt) | Novas composições à base de taxóides | |
| ES2972897T3 (es) | Composiciones descongestionantes nasales que comprenden mentol, dexpantenol e hialuronato de sodio | |
| JP2023011818A (ja) | エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 | |
| EP4225271A1 (en) | Compositions and methods for lowering intracranial pressure by intranasal agent administration | |
| CN101088499B (zh) | 细辛脑干乳剂及其制备方法与应用 | |
| HK1172272A (en) | Pharmaceutical composition comprising propofol | |
| WO2025205960A1 (ja) | エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ | |
| HK40054634B (en) | Aqueous paediatric retinol formulations |